A legislative committee in Maine has begun discussions on a bill that would effectively legalize the possession of low-level psilocybin for adults aged 21 and older. The bill, known as LD 1034, was introduced by Rep. Grayson Lookner (D) and aims to amend state laws concerning the possession of scheduled drugs. Under this proposal, individuals would be allowed to possess up to one ounce of psilocybin, but the bill does not include provisions for the production, distribution, or commercial sale of the substance.
During a hearing held by the legislature’s Criminal Justice and Public Safety Committee, Lookner described the bill as “a common sense shift in how we view plant medicine in Maine.” He emphasized that the purpose of the legislation is to prevent adults from facing criminal penalties for possessing a natural substance that many find beneficial for their well-being. Lookner believes that adults should have the freedom to make choices about what they consume, particularly regarding natural medicines that can be found in Maine.
The bill is not intended to promote drug use, according to Lookner. Instead, it seeks to shift focus from punishment to healing. He remarked, “Psilocybin mushrooms grow naturally in our forests and fields, just as they have for thousands of years.” Lookner highlighted that psilocybin is a natural organism with a long history of medicinal use across various cultures.
Lookner pointed out that the reform could particularly benefit military veterans suffering from PTSD and individuals in end-of-life care. He noted that these groups often struggle with traditional pharmaceuticals that fail to provide relief, stating, “When someone is suffering at the end of their life, or a veteran is haunted by trauma, shouldn’t they have every available option for their relief?”
Following Lookner’s introduction, lawmakers engaged in a discussion about the current legal status of psilocybin and its effects. Rep. Donald Ardell (R) referenced information from the National Institutes of Health (NIH), which noted that psilocybin microdosing can lead to side effects such as insomnia, anxiety, and physical discomfort. Ardell questioned how the proposed legislation would align with the NIH’s warnings about the potential dangers of psilocybin, especially for individuals with certain mental health conditions.
In response, Lookner compared psilocybin to alcohol, arguing that both substances can pose risks but are not treated as criminal offenses. He stated, “This is about allowing adults to make their own decisions, primarily and secondarily.” He also mentioned that many successful individuals in high positions engage in microdosing.
During the hearing, Lookner characterized the bill as a “decriminalization bill,” clarifying that it does not legalize psilocybin or create a recreational market. He emphasized, “It just says if an adult has a small amount of this compound, they can’t face criminal charges for it.” When asked about the possession limit set at one ounce, he indicated that he was open to reconsidering that figure based on expert feedback.
Typically, a standard dose of psilocybin mushrooms is a few grams, while microdosing involves taking a small fraction of a gram at a time.
English 
Spanish 
German 
Czech